Business Context and Reporting Period
Serina Therapeutics, Inc. (NYSE American: SER) filed a Form 8-K on August 21, 2026, reporting the entry into a Material Definitive Agreement. The Company, a Delaware corporation headquartered in Huntsville, Alabama, entered into a Common Stock Purchase Agreement and a Registration Rights Agreement with Roth Principal Investments, LLC.
Key Financial Metrics and Transaction Terms
- Maximum Offering Size: Up to $25,000,000 of newly issued common stock.
- Term: Up to 36 months from the Commencement Date.
- Pricing Mechanism: Shares are sold at a discount to the Volume Weighted Average Price (VWAP).
- Market Open/Intraday Purchases: 7% discount (0.93 multiplier) if cumulative sales are under $12.5 million; 3% discount (0.97 multiplier) if cumulative sales are $12.5 million or more.
- Pre-Market/Post-Market Purchases: 7% discount (0.93 multiplier) if cumulative sales are under $12.5 million; 5% discount (0.95 multiplier) if cumulative sales are $12.5 million or more.
- Exchange Cap: Issuance is limited to 19.99% of outstanding shares (5,077,554 shares) unless the purchase price equals or exceeds the Base Price of $2.7695.
- Beneficial Ownership Limit: Roth Principal Investments cannot beneficially own more than 4.99% of outstanding shares.
- Transaction Costs:
- Legal fee reimbursement to Roth: $100,000 upfront plus up to $7,500 per fiscal quarter.
- Qualified Independent Underwriter (Compass Point) fee: Up to $50,000.
Material Changes and Operational Impact
This filing represents a new financing facility rather than a change in historical financial performance. The Company retains sole discretion over the timing and amount of any sales, with no obligation to sell any securities. The agreement includes a "Standstill" provision prohibiting the Company from offering or selling other equity securities without Roth's consent until the Registration Statement is effective. Additionally, the Company is restricted from entering into other "Variable Rate Transactions" (e.g., other equity lines of credit) during the term.
Guidance, Outlook, and Risks
- Use of Proceeds: Net proceeds, if any, are intended for working capital and general corporate purposes.
- Termination: The Company may terminate the agreement at any time after Commencement with 10 trading days' notice without penalty, provided legal fees are paid. The agreement also terminates automatically if the stock is delisted or if bankruptcy proceedings commence.
- Risks: The transaction involves potential dilution to existing shareholders. The pricing mechanism includes discounts to market price, which may impact the stock price. The Company is subject to a standstill on other equity issuances until the registration statement is effective.
Investor Verification Checklist
- Verify the current trading price of SER relative to the Base Price of $2.7695 to determine if the 19.99% Exchange Cap applies.
- Confirm the status of the Registration Statement filed with the SEC to determine when the Standstill restriction on other equity sales will be lifted.
- Monitor future 8-K filings for actual sales notices to assess the frequency and volume of share issuance under this facility.
- Review the Company's cash position to understand the immediate necessity of utilizing this facility versus other funding sources.